Dasatinib 2024 medical insurance price

Dasatinib is an effective anti-tumor drug mainly used to treat leukemia, especially patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Dasatinib is a protein kinase inhibitor that exerts therapeutic effects by inhibiting multiple oncogenic kinases. In terms of clinical indications, it is mainly used to treat Ph+ CML patients who are resistant or intolerant to imatinib mesylate, whether they are adult patients in the chronic phase, accelerated phase or blast phase (including blast myeloblastosis and blast crisis).

Dasatinib should be taken under the guidance of a physician experienced in the diagnosis and treatment of leukemia. For patients with Ph+ chronic phase CML, the recommended starting dose is 100 mg daily, while for patients with accelerated phase or blast crisis, the recommended starting dose is 70 mg twice daily. Tablets must be swallowed whole and not crushed or broken.

Contraindicated in patients allergic to dasatinib or any excipients. It is not recommended for use by pregnant and lactating women, and there is no relevant data to support its safety in these populations. Patients with liver damage should use it with caution and have their liver function checked regularly during use.

Today, dasatinib has been launched in China and is also covered by my country’s Class B medical insurance. in the country, consumers can choose the original dasatinib or domestic generic drugs. Each box of the original drug contains 60 tablets (50 mg each), and the price after medical insurance reimbursement is about 5,000 yuan. On the other hand, domestic generic drugs cost about 400 yuan per box of 7 tablets (50mg each). In addition, it is understood that India and Bangladesh also have a variety of generic versions of dasatinib on the market, including 50 mg * 60 tablets, priced between 600 and 1,000 yuan. Compared with domestic products, these overseas generic drugs are obviously more cost-effective.

Overall, dasatinib provides a new treatment option for leukemia patients who are resistant or intolerant to imatinib mesylate, which delays disease progression and improves patients' quality of life by inhibiting oncogenic kinases. When using, patients should strictly follow medical instructions to ensure the safety and effectiveness of treatment.